Current opinion in hematology
-
Curr. Opin. Hematol. · Mar 2007
ReviewThe role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
The aim of this article is to discuss the relevant pathobiologic effects of lenalidomide and the most recent clinical evidence to support its use in patients with myelodysplastic syndrome. ⋯ Lenalidomide is an active immunomodulatory agent for the treatment of myelodysplastic syndrome with encouraging erythropoetic and cytogenetic remitting activity that is karyotype dependent.